Second, we found that CAP-related nAChR and α7nAChR agonist treatments exert lung-protective effects and significantly improve inflammation in lung injury animal models, suggesting that these agents could be potential drug candidates for ARDS treatment. The gene discussed is CHRNA4; the disease is acute respiratory distress syndrome.